Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treating cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsaturated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Intervention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher levels of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was > 0.75. Furthermore, the ratio of prostaglandin (PG) I3 and PGI2 to thromboxane A2 (TXA2) ([PGI2 + PGI3]/TXA2) was determined to have a linear relationship with the EPA/AA ratio as follows: (PGI2 + PGI3)/TXA2 =λ + π* (EPA/AA). Like PGI2, PGI3 not only inhibits platelet aggregation and vasoconstriction, but also is assumed to reduce cardiac ischemic injury and arteriosclerosis and promote angiogenesis. Thus, the effects of EPA in reducing the risk of CVD could be mediated by biological action of PGI3 in addition to hypotriglyceridemic action of EPA. Compared with DHA, EPA administration increases the EPA/AA ratio and the (PGI2 + PGI3)/TXA2 balance to a state that inhibits the onset and/or progression of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Fatty acid composition of the plasma lipids in Greenland Eskimos
Dyerberg, J., Bang, H., & Hjørne, N. (1975) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/28.9.958 · Cited by 877
Thies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739
Kromann, N., & Green, A. (1980) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1980.tb01221.x · Cited by 713
PLASMA LIPID AND LIPOPROTEIN PATTERN IN GREENLANDIC WEST-COAST ESKIMOS
Bang, H. O., Dyerberg, J., & Nielsen, A. B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91658-8 · Cited by 690
Hooper, L., Thompson, R. L., Harrison, R. A., Summerbell, C. D., Ness, A. R., Moore, H. J., Worthington, H. V., Durrington, P. N., Higgins, J. P. T., Capps, N. E., et al. (2006) · BMJ · doi:10.1136/bmj.38755.366331.2f · Cited by 676
Mori, T. A., Burke, V., Puddey, I. B., Watts, G. F., O’Neal, D. N., Best, J. D., & Beilin, L. J. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1085 · Cited by 588
Dolecek, T. A. (1992) · Experimental Biology and Medicine · doi:10.3181/00379727-200-43413 · Cited by 410
Cited by
Saini, R. K., & Keum, Y.-S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.04.049 · Cited by 1,281
Saini, R. K., Prasad, P., Sreedhar, R. V., Akhilender Naidu, K., Shang, X., & Keum, Y.-S. (2021) · Antioxidants · doi:10.3390/antiox10101627 · Cited by 337
“Likewise, recent evidence shows that consumption of EPA alone is largely associated with a reduction in cardiovascular diseases [21,22], whereas DHA is important for neonatal brain development and mental and cognitive effects [23,24].”
BackgroundDietary and Pharmacological Fatty Acids and Cardiovascular Health
Wu, H., Xu, L., & Ballantyne, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz174 · Cited by 59
Prokopiou, E., Kolovos, P., Kalogerou, M., Neokleous, A., Papagregoriou, G., Deltas, C., Malas, S., & Georgiou, T. (2017) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2016-000056 · Cited by 16
“Thus, the effects of EPA in reducing the risk of CVD could be mediated by the biological action of PGI3 in addition to the hypo-triglyceridemic action of EPA.”
BackgroundShaikh, N. A., Yantha, J., Shaikh, S., Rowe, W., Laidlaw, M., Cockerline, C., Ali, A., Holub, B., & Jackowski, G. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2132-1 · Cited by 16
Metadata
- Authors
- Ohnishi, H., & Saito, Y.
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2013
- Volume
- 20
- Issue
- 12
- Pages
- 861-877
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- OpenAlex
- W2124504374
- Cited by
- 88
- References
- 14
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio. https://app.cochat.ai/papers/10.5551/jat.18002
- The paper
- Ohnishi, H., & Saito, Y. (2013). Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.18002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.